Welcome to our dedicated page for Nanalysis Sci news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on Nanalysis Sci stock.
Nanalysis Scientific Corp. (OTCQX: NSCIF; TSXV: NSCI; FRA: 1N1) is an analytical laboratory instrument manufacturer focused on portable Nuclear Magnetic Resonance (NMR) spectrometers and related magnetic resonance technology, alongside a Security Services division centered on airport security equipment maintenance. The news flow around Nanalysis reflects both its technology roadmap and its operational and financial performance.
On this page, readers can follow company announcements on quarterly and year-to-date financial results, where Nanalysis reports trends in product sales, security services revenue, gross margins, Adjusted EBITDA, and normalized net loss. These releases often discuss the impact of macroeconomic conditions, such as tariff and trade uncertainty, on capital equipment demand, as well as the effects of cost-reduction and continuous improvement programs in manufacturing and services.
News items also cover business development and technology milestones, including OEM and licensing agreements for MRI consoles, collaborations with software providers like Wiley’s KnowItAll for NMR data analysis, and regulatory developments such as the acceptance of a benchtop NMR assay by the United States Pharmacopeia and the European Pharmacopoeia. Updates on the company’s Security Services segment, including operational changes in its airport security maintenance business and the execution of its long-term contract with the Canadian Air Transport Security Authority (CATSA), are another recurring theme.
Investors and observers can also see announcements related to financing activities, such as private placements of units and promissory notes, amendments to loan facilities, and management changes. For anyone tracking NSCIF, this news feed provides a consolidated view of how Nanalysis is managing its benchtop NMR and MRI technology platforms, its security services operations, and its capital structure over time.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) announced the successful closing of the first tranche of its non-brokered private placement on April 21, 2023. The company issued 3,738,667 units at $0.60 each, raising gross proceeds of $2,243,200. Each unit consists of one common share and one warrant, allowing the purchase of a share at $0.80 until one year after the closure. The proceeds will enhance working capital, with a second tranche expected to close around May 1, 2023. Finders received aggregate fees of $12,600 in connection with the first closing. The securities are subject to a four-month holding period post-closing and need final acceptance from the TSX Venture Exchange.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) has announced plans for a non-brokered private placement of up to 5,833,333 units at $0.60 each, aiming for total gross proceeds of $3.5 million. This move is strategically designed to bolster the company's balance sheet as it approaches the rollout of a $160 million service contract with CATSA Airport. CEO Sean Krakiwsky emphasized the importance of this contract for providing stable, long-term revenue and outlined efforts to integrate their service organization with existing product lines, enhancing profitability. The offering’s completion is subject to TSX Venture Exchange approval, and insiders may participate in a subsequent closing.
Nanalysis Scientific Corp. announced a collaboration with QUAD Systems to debut the 400MHz High Field NMR system at the Experimental Nuclear Magnetic Resonance Conference (ENC 2023), held from April 16-20, 2023, in Pacific Grove, California. Nanalysis provided critical components for this new system, signifying a strategic move into the high-field NMR market, valued at over a billion dollars annually. Sean Krakiwsky, CEO of Nanalysis, expressed excitement about this venture, which aligns with their growth in portable NMR technology. The collaboration with QUAD Systems aims to enhance their market position and innovation in NMR spectroscopy. Nanalysis holds a 43% stake in QUAD, with an option to acquire the remaining shares, strengthening their partnership in advancing NMR capabilities.
Nanalysis Scientific Corp. will host a conference call on April 27, 2023 at 5:00 PM ET to discuss financial results for the quarter and year ending December 31, 2022. CEO Sean Krakiwsky and CFO Randall McRae will lead the call. Investors can join via phone or online. A European Q&A session is scheduled for April 28, 2023 at 8:30 AM ET. Nanalysis, trading under NSCI and NSCIF, specializes in portable NMR machines and MRI technology for various industries, including healthcare and pharmaceuticals. The company recently expanded its capabilities with the acquisition of K'Prime Technologies and holds a 43% stake in Quad Systems AG.
Nanalysis Scientific Corp. (NSCIF) will participate in the Industrial Tech Virtual Conference, hosted by M-Vest, on March 21, 2023, at 1 p.m. ET. CEO Sean Krakiwsky has been invited to join the panel discussing opportunities in Industrial and Medical markets. The conference will showcase trends and opportunities driven by new technologies in various sectors, enhancing infrastructure and manufacturing resiliency. Nanalysis, known for its Nuclear Magnetic Resonance (NMR) devices, continues to innovate with products like the portable NMReady-60™.
Attendance is free for M-Vest members.
Nanalysis Scientific Corp. (NSCIF) has announced the grant of 335,000 stock options to its Directors and Officers, allowing them to purchase shares at $1.10 each for five years. The options will vest over three years, with one-third vesting annually. Additionally, 135,000 Restricted Stock Units (RSUs) were granted to Directors, also vesting over the same period. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) spectrometers and has expanded its market presence following the acquisition of K'Prime, enhancing its sales and service capabilities in North America.
Nanalysis Scientific Corp. announces the appointment of Randall McRae as Chief Financial Officer. Previously serving as interim CFO for seven months, McRae brings over 15 years of experience from MNP LLP and co-founding McRally LLP, a cloud accounting firm. His appointment aims to foster company growth and align with Nanalysis's innovative trajectory in portable NMR technology. The company specializes in developing portable Nuclear Magnetic Resonance (NMR) machines for various industries, including oil and gas, pharmaceuticals, and chemicals. Nanalysis aims to capitalize on new global market opportunities through its recent acquisitions and partnerships.
Nanalysis Scientific Corp. reported strong growth in Q3 2022, achieving consolidated revenue of $6,878K, a 106% increase from the prior year. The company attributes this growth to an uptick in product sales and ongoing airport security services. Despite a net loss of $(2,599K) for the quarter, financial metrics indicate operational improvements. The company received $1.5 million from a federal funding program to support growth and has consolidated its credit facilities to enhance liquidity. CEO Sean Krakiwsky expressed confidence in future growth, driven by increased demand for its 100 MHz NMR product and the CATSA contract.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) will hold a conference call on November 29, 2022, at 5:00 PM ET to discuss third-quarter results for the period ending September 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the call. A European Q&A session is scheduled for November 30, 2022, at 8:30 AM ET. Investors can participate through a live webcast or by phone. Nanalysis specializes in portable Nuclear Magnetic Resonance devices for various industries and continues to expand its product lineup.
Nanalysis Scientific Corp. announced preliminary Q3 2022 revenues expected to exceed $6.8 million, marking a year-over-year growth of over 100%. The company is optimistic about recovery in its core NMR business and anticipates significant billings from its CATSA service contract in Q4 2022. Noteworthy achievements this quarter include record shipments of 20 units of the 100MHz NMR and a C$1.1 million contract for a custom MRI system in France. CEO Sean Krakiwsky will present at the LD Micro Conference on Oct. 25.
FAQ
What is the current stock price of Nanalysis Sci (NSCIF)?
What is the market cap of Nanalysis Sci (NSCIF)?
